IMPLANTABLE INFUSION PUMP MEDICARE COVERAGE
This article was originally published in The Gray Sheet
Executive SummaryIMPLANTABLE INFUSION PUMP MEDICARE COVERAGE for five implantation procedures in ambulatory surgical centers would be dropped under a proposed revision to the Medicare ASC coverage list. The Dec. 14 proposal states that coverage for devices implanted in ASCs must be limited to certain applications of intra-arterial pumps.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.